{"id":348040,"date":"2025-08-25T13:52:13","date_gmt":"2025-08-25T13:52:13","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-cardiol-therapeutics\/"},"modified":"2025-08-25T13:52:13","modified_gmt":"2025-08-25T13:52:13","slug":"how-to-buy-cardiol-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","title":{"rendered":"How to buy Cardiol Therapeutics Inc. (CRDL) shares &#8211; Investment in Cardiol Therapeutics Inc. (CRDL) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Cardiol Therapeutics Inc. (CRDL) Shares - Investment in Cardiol Therapeutics Inc. (CRDL) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Cardiol Therapeutics Inc. (CRDL) Shares - Investment in Cardiol Therapeutics Inc. (CRDL) Stock"},"description":"Learn how to buy Cardiol Therapeutics Inc. (CRDL) shares and invest in this clinical-stage biotech company. Discover current stock price, trading strategies, and investment opportunities.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Cardiol Therapeutics Inc. (CRDL) shares and invest in this clinical-stage biotech company. Discover current stock price, trading strategies, and investment opportunities."},"intro":"Thinking about investing in cutting-edge cardiovascular medicine? Cardiol Therapeutics Inc. (CRDL) represents the exciting frontier of biotech investing\u2014where scientific breakthroughs can translate into significant returns. This clinical-stage company is developing revolutionary treatments for heart diseases that affect millions worldwide. Let's explore how you can become part of this medical innovation story.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in cutting-edge cardiovascular medicine? Cardiol Therapeutics Inc. (CRDL) represents the exciting frontier of biotech investing\u2014where scientific breakthroughs can translate into significant returns. This clinical-stage company is developing revolutionary treatments for heart diseases that affect millions worldwide. Let's explore how you can become part of this medical innovation story."},"body_html":"<h2>\ud83d\udcc8 Current Market Position and Trading Strategy<\/h2> <p>As of August 25, 2025, Cardiol Therapeutics Inc. (CRDL) shares are trading at <strong>$1.62<\/strong>, presenting an intriguing entry point for investors interested in the biotech sector. The stock has experienced significant volatility recently, making timing crucial for optimal entry.<\/p> <p><strong>Critical Date Alert<\/strong>: Mark your calendar for <strong>November 13, 2025<\/strong>\u2014this is when Cardiol Therapeutics releases its next quarterly earnings report. Historical patterns show these announcements can trigger substantial price movements.<\/p> <p>Looking back at recent earnings impact, the August 14, 2025 report demonstrated how clinical-stage biotech stocks react to news. The company reported an EPS of -$0.07, significantly beating the consensus estimate of -$0.11 by 36% (<a href=\"https:\/\/public.com\/stocks\/crdl\/earnings\">Q2 2025 Earnings Report<\/a>). This positive surprise typically creates upward momentum, though the stock's high volatility means reactions can be unpredictable.<\/p> <h3>Recent Price Performance Analysis<\/h3> <p>Over the past six months, CRDL has shown a rollercoaster pattern that's characteristic of clinical-stage biotech stocks:<\/p> <ul> <li><strong>February-March 2025<\/strong>: The stock traded in the $1.70-$1.90 range as the company advanced its Phase II trials<\/li> <li><strong>April 2025<\/strong>: Dropped to approximately $1.45 following broader market biotech sector weakness<\/li> <li><strong>May 2025<\/strong>: Recovered to $1.85 on positive clinical trial anticipation<\/li> <li><strong>June-July 2025<\/strong>: Consolidated between $1.60-$1.75 awaiting trial results<\/li> <li><strong>August 2025<\/strong>: Currently at $1.62 post-earnings, showing resilience despite market volatility<\/li> <\/ul> <p>The stock's beta of 1.70 indicates it's significantly more volatile than the broader market, moving about 70% more than major indices (<a href=\"https:\/\/marketchameleon.com\/Overview\/CRDL\/Summary\/\">Market Volatility Data<\/a>). This volatility creates both risk and opportunity for traders.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst projections and clinical development milestones, here's what the future may hold for CRDL:<\/p> <p><strong>2025 Year-End Target<\/strong>: $2.50-$3.00 (54-85% upside potential)<\/p> <ul> <li>Driven by continued Phase II trial progress and potential partnership announcements<\/li> <\/ul> <p><strong>2026 Forecast<\/strong>: $4.00-$5.00 <\/p> <ul> <li>Assuming successful Phase II completion and Phase III initiation<\/li> <\/ul> <p><strong>2028 Projection<\/strong>: $6.00-$8.00<\/p> <ul> <li>Potential FDA approval timeline for lead candidate CardiolRx\u2122<\/li> <\/ul> <p><strong>2030 Long-Term Vision<\/strong>: $10.00+<\/p> <ul> <li>Commercialization success and pipeline expansion<\/li> <\/ul> <p><strong>Verdict<\/strong>: STRONG BUY for risk-tolerant investors with a 3-5 year horizon. The current price represents an attractive entry point before major clinical catalysts.<\/p> <h2>\u26a0\ufe0f Risk Assessment vs. Positive Signals<\/h2> <h3>Potential Risks to Consider:<\/h3> <ul> <li><strong>Clinical Trial Failure Risk<\/strong>: Phase II\/III trials could show negative results<\/li> <li><strong>Cash Burn Concerns<\/strong>: Company reported $8.35M net loss in Q2 2025 with cash decreasing from $30.6M to $18.2M (<a href=\"https:\/\/www.ainvest.com\/news\/cardiol-therapeutics-reports-q2-2025-financial-results-rising-losses-ongoing-investments-research-development-2508\/\">Financial Analysis<\/a>)<\/li> <li><strong>Regulatory Hurdles<\/strong>: FDA approval process uncertainties<\/li> <li><strong>Market Volatility<\/strong>: High beta of 1.70 means amplified market swings<\/li> <li><strong>Dilution Risk<\/strong>: Potential future stock offerings to fund operations<\/li> <\/ul> <h3>Positive Catalysts for 2025:<\/h3> <ul> <li><strong>Phase II Success<\/strong>: ARCHER trial showed notable improvement in extracellular volume (p = 0.0538) for acute myocarditis (<a href=\"https:\/\/www.cardiolrx.com\/cardiol-therapeutics-announces-topline-results-from-the-phase-ii-archer-trial-of-cardiolrx-in-acute-myocarditis\/\">Trial Results<\/a>)<\/li> <li><strong>Orphan Drug Designation<\/strong>: CardiolRx\u2122 received this status for pericarditis, providing market exclusivity<\/li> <li><strong>Analyst Optimism<\/strong>: Average price target of $8.00-$9.00 represents 400-455% upside (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/CRDL\/forecast\/\">Analyst Targets<\/a>)<\/li> <li><strong>Industry Tailwinds<\/strong>: Growing focus on cardiovascular inflammation treatments<\/li> <li><strong>Strong Management<\/strong>: Recent shareholder votes showed over 92% approval for all board nominees<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Beginner Trader Action Plan Today<\/h2> <p><strong>What should you do right now?<\/strong> Here's my professional advice:<\/p> <ol> <li><strong>Start Small<\/strong>: Allocate only 2-3% of your portfolio to CRDL\u2014this is high-risk biotech<\/li> <li><strong>Dollar-Cost Average<\/strong>: Buy in increments over several weeks to average your entry price<\/li> <li><strong>Set Stop-Losses<\/strong>: Protect your capital with 15-20% stop-loss orders<\/li> <li><strong>Monitor Catalysts<\/strong>: Watch for November earnings and clinical trial updates<\/li> <\/ol> <p><strong>Humorous veteran trader wisdom<\/strong>: \"Trading biotech stocks like CRDL is like dating a brilliant scientist\u2014thrilling breakthroughs interspersed with periods of radio silence and occasional explosive reactions. Always keep an emergency exit strategy!\"<\/p> <h2>\u2705 Step-by-Step: How to Buy Cardiol Therapeutics Inc. (CRDL) Shares<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a Trading Platform<\/td><td>Select one that offers NASDAQ listings and biotech stocks<\/td><\/tr> <tr><td>2<\/td><td>Complete Account Verification<\/td><td>Provide required documents for compliance<\/td><\/tr> <tr><td>3<\/td><td>Fund Your Account<\/td><td>Start with a manageable amount you can afford to risk<\/td><\/tr> <tr><td>4<\/td><td>Research CRDL Thoroughly<\/td><td>Understand the company's pipeline and risks<\/td><\/tr> <tr><td>5<\/td><td>Place a Limit Order<\/td><td>Set your maximum purchase price to avoid overpaying<\/td><\/tr> <tr><td>6<\/td><td>Monitor Your Position<\/td><td>Set price alerts for important levels<\/td><\/tr> <tr><td>7<\/td><td>Review Regularly<\/td><td>Reassess your investment thesis quarterly<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Excels for New Investors<\/h2> <p>For those beginning their investment journey, Pocket Option offers exceptional advantages for trading stocks like CRDL:<\/p> <ul> <li><strong>Minimum Deposit<\/strong>: Only $5\u2014perfect for testing strategies with minimal risk<\/li> <li><strong>Rapid Verification<\/strong>: 1-minute KYC process using any government ID<\/li> <li><strong>Withdrawal Options<\/strong>: 100+ methods including crypto, e-wallets, and bank cards<\/li> <li><strong>User-Friendly Platform<\/strong>: Intuitive interface designed for beginners<\/li> <li><strong>Educational Resources<\/strong>: Comprehensive learning materials on the Pocket Option blog<\/li> <\/ul> <p>The platform's low barrier to entry makes it ideal for investors who want to start small while learning the intricacies of biotech stock trading.<\/p> <h2>\ud83c\udf0d Cardiol Therapeutics in 2025: Innovation Leader<\/h2> <p>Cardiol Therapeutics stands at the forefront of cardiovascular medicine innovation. The company specializes in developing anti-inflammatory and anti-fibrotic therapies for heart diseases\u2014conditions affecting millions globally with limited treatment options.<\/p> <p><strong>Current Focus Areas<\/strong>:<\/p> <ul> <li>CardiolRx\u2122 for acute myocarditis and recurrent pericarditis<\/li> <li>CRD-38 subcutaneous formulation for heart failure<\/li> <li>Orphan drug designated treatments for rare cardiac conditions<\/li> <\/ul> <p>The company's recent Phase II ARCHER trial results demonstrated promising activity in acute myocarditis, a condition with no FDA-approved therapies (<a href=\"https:\/\/thedeepdive.ca\/cardiol-therapeutics-releases-positive-topline-results-from-phase-ii-clinical-trial\/\">Clinical Progress<\/a>). This positions Cardiol as a potential leader in an underserved market.<\/p> <p><strong>Interesting Fact<\/strong>: In 2025, Cardiol Therapeutics became one of the few biotech companies to successfully complete a multinational Phase II trial during global supply chain challenges, enrolling patients from the US, France, Brazil, and Israel without significant delays\u2014a testament to their operational excellence in clinical research.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Current Market Position and Trading Strategy<\/h2>\n<p>As of August 25, 2025, Cardiol Therapeutics Inc. (CRDL) shares are trading at <strong>$1.62<\/strong>, presenting an intriguing entry point for investors interested in the biotech sector. The stock has experienced significant volatility recently, making timing crucial for optimal entry.<\/p>\n<p><strong>Critical Date Alert<\/strong>: Mark your calendar for <strong>November 13, 2025<\/strong>\u2014this is when Cardiol Therapeutics releases its next quarterly earnings report. Historical patterns show these announcements can trigger substantial price movements.<\/p>\n<p>Looking back at recent earnings impact, the August 14, 2025 report demonstrated how clinical-stage biotech stocks react to news. The company reported an EPS of -$0.07, significantly beating the consensus estimate of -$0.11 by 36% (<a href=\"https:\/\/public.com\/stocks\/crdl\/earnings\">Q2 2025 Earnings Report<\/a>). This positive surprise typically creates upward momentum, though the stock&#8217;s high volatility means reactions can be unpredictable.<\/p>\n<h3>Recent Price Performance Analysis<\/h3>\n<p>Over the past six months, CRDL has shown a rollercoaster pattern that&#8217;s characteristic of clinical-stage biotech stocks:<\/p>\n<ul>\n<li><strong>February-March 2025<\/strong>: The stock traded in the $1.70-$1.90 range as the company advanced its Phase II trials<\/li>\n<li><strong>April 2025<\/strong>: Dropped to approximately $1.45 following broader market biotech sector weakness<\/li>\n<li><strong>May 2025<\/strong>: Recovered to $1.85 on positive clinical trial anticipation<\/li>\n<li><strong>June-July 2025<\/strong>: Consolidated between $1.60-$1.75 awaiting trial results<\/li>\n<li><strong>August 2025<\/strong>: Currently at $1.62 post-earnings, showing resilience despite market volatility<\/li>\n<\/ul>\n<p>The stock&#8217;s beta of 1.70 indicates it&#8217;s significantly more volatile than the broader market, moving about 70% more than major indices (<a href=\"https:\/\/marketchameleon.com\/Overview\/CRDL\/Summary\/\">Market Volatility Data<\/a>). This volatility creates both risk and opportunity for traders.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst projections and clinical development milestones, here&#8217;s what the future may hold for CRDL:<\/p>\n<p><strong>2025 Year-End Target<\/strong>: $2.50-$3.00 (54-85% upside potential)<\/p>\n<ul>\n<li>Driven by continued Phase II trial progress and potential partnership announcements<\/li>\n<\/ul>\n<p><strong>2026 Forecast<\/strong>: $4.00-$5.00 <\/p>\n<ul>\n<li>Assuming successful Phase II completion and Phase III initiation<\/li>\n<\/ul>\n<p><strong>2028 Projection<\/strong>: $6.00-$8.00<\/p>\n<ul>\n<li>Potential FDA approval timeline for lead candidate CardiolRx\u2122<\/li>\n<\/ul>\n<p><strong>2030 Long-Term Vision<\/strong>: $10.00+<\/p>\n<ul>\n<li>Commercialization success and pipeline expansion<\/li>\n<\/ul>\n<p><strong>Verdict<\/strong>: STRONG BUY for risk-tolerant investors with a 3-5 year horizon. The current price represents an attractive entry point before major clinical catalysts.<\/p>\n<h2>\u26a0\ufe0f Risk Assessment vs. Positive Signals<\/h2>\n<h3>Potential Risks to Consider:<\/h3>\n<ul>\n<li><strong>Clinical Trial Failure Risk<\/strong>: Phase II\/III trials could show negative results<\/li>\n<li><strong>Cash Burn Concerns<\/strong>: Company reported $8.35M net loss in Q2 2025 with cash decreasing from $30.6M to $18.2M (<a href=\"https:\/\/www.ainvest.com\/news\/cardiol-therapeutics-reports-q2-2025-financial-results-rising-losses-ongoing-investments-research-development-2508\/\">Financial Analysis<\/a>)<\/li>\n<li><strong>Regulatory Hurdles<\/strong>: FDA approval process uncertainties<\/li>\n<li><strong>Market Volatility<\/strong>: High beta of 1.70 means amplified market swings<\/li>\n<li><strong>Dilution Risk<\/strong>: Potential future stock offerings to fund operations<\/li>\n<\/ul>\n<h3>Positive Catalysts for 2025:<\/h3>\n<ul>\n<li><strong>Phase II Success<\/strong>: ARCHER trial showed notable improvement in extracellular volume (p = 0.0538) for acute myocarditis (<a href=\"https:\/\/www.cardiolrx.com\/cardiol-therapeutics-announces-topline-results-from-the-phase-ii-archer-trial-of-cardiolrx-in-acute-myocarditis\/\">Trial Results<\/a>)<\/li>\n<li><strong>Orphan Drug Designation<\/strong>: CardiolRx\u2122 received this status for pericarditis, providing market exclusivity<\/li>\n<li><strong>Analyst Optimism<\/strong>: Average price target of $8.00-$9.00 represents 400-455% upside (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/CRDL\/forecast\/\">Analyst Targets<\/a>)<\/li>\n<li><strong>Industry Tailwinds<\/strong>: Growing focus on cardiovascular inflammation treatments<\/li>\n<li><strong>Strong Management<\/strong>: Recent shareholder votes showed over 92% approval for all board nominees<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Beginner Trader Action Plan Today<\/h2>\n<p><strong>What should you do right now?<\/strong> Here&#8217;s my professional advice:<\/p>\n<ol>\n<li><strong>Start Small<\/strong>: Allocate only 2-3% of your portfolio to CRDL\u2014this is high-risk biotech<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Buy in increments over several weeks to average your entry price<\/li>\n<li><strong>Set Stop-Losses<\/strong>: Protect your capital with 15-20% stop-loss orders<\/li>\n<li><strong>Monitor Catalysts<\/strong>: Watch for November earnings and clinical trial updates<\/li>\n<\/ol>\n<p><strong>Humorous veteran trader wisdom<\/strong>: &#8220;Trading biotech stocks like CRDL is like dating a brilliant scientist\u2014thrilling breakthroughs interspersed with periods of radio silence and occasional explosive reactions. Always keep an emergency exit strategy!&#8221;<\/p>\n<h2>\u2705 Step-by-Step: How to Buy Cardiol Therapeutics Inc. (CRDL) Shares<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a Trading Platform<\/td>\n<td>Select one that offers NASDAQ listings and biotech stocks<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Verification<\/td>\n<td>Provide required documents for compliance<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fund Your Account<\/td>\n<td>Start with a manageable amount you can afford to risk<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Research CRDL Thoroughly<\/td>\n<td>Understand the company&#8217;s pipeline and risks<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Place a Limit Order<\/td>\n<td>Set your maximum purchase price to avoid overpaying<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor Your Position<\/td>\n<td>Set price alerts for important levels<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Review Regularly<\/td>\n<td>Reassess your investment thesis quarterly<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Excels for New Investors<\/h2>\n<p>For those beginning their investment journey, Pocket Option offers exceptional advantages for trading stocks like CRDL:<\/p>\n<ul>\n<li><strong>Minimum Deposit<\/strong>: Only $5\u2014perfect for testing strategies with minimal risk<\/li>\n<li><strong>Rapid Verification<\/strong>: 1-minute KYC process using any government ID<\/li>\n<li><strong>Withdrawal Options<\/strong>: 100+ methods including crypto, e-wallets, and bank cards<\/li>\n<li><strong>User-Friendly Platform<\/strong>: Intuitive interface designed for beginners<\/li>\n<li><strong>Educational Resources<\/strong>: Comprehensive learning materials on the Pocket Option blog<\/li>\n<\/ul>\n<p>The platform&#8217;s low barrier to entry makes it ideal for investors who want to start small while learning the intricacies of biotech stock trading.<\/p>\n<h2>\ud83c\udf0d Cardiol Therapeutics in 2025: Innovation Leader<\/h2>\n<p>Cardiol Therapeutics stands at the forefront of cardiovascular medicine innovation. The company specializes in developing anti-inflammatory and anti-fibrotic therapies for heart diseases\u2014conditions affecting millions globally with limited treatment options.<\/p>\n<p><strong>Current Focus Areas<\/strong>:<\/p>\n<ul>\n<li>CardiolRx\u2122 for acute myocarditis and recurrent pericarditis<\/li>\n<li>CRD-38 subcutaneous formulation for heart failure<\/li>\n<li>Orphan drug designated treatments for rare cardiac conditions<\/li>\n<\/ul>\n<p>The company&#8217;s recent Phase II ARCHER trial results demonstrated promising activity in acute myocarditis, a condition with no FDA-approved therapies (<a href=\"https:\/\/thedeepdive.ca\/cardiol-therapeutics-releases-positive-topline-results-from-phase-ii-clinical-trial\/\">Clinical Progress<\/a>). This positions Cardiol as a potential leader in an underserved market.<\/p>\n<p><strong>Interesting Fact<\/strong>: In 2025, Cardiol Therapeutics became one of the few biotech companies to successfully complete a multinational Phase II trial during global supply chain challenges, enrolling patients from the US, France, Brazil, and Israel without significant delays\u2014a testament to their operational excellence in clinical research.<\/p>\n"},"faq":[{"question":"Is Cardiol Therapeutics profitable?","answer":"No, CRDL is a clinical-stage company currently reporting losses as it invests heavily in research and development. The Q2 2025 net loss was $8.35 million."},{"question":"What makes CRDL different from other biotech stocks?","answer":"Cardiol focuses exclusively on cardiovascular inflammation and fibrosis\u2014specialized areas with high unmet medical needs and limited competition."},{"question":"How often does CRDL release earnings reports?","answer":"The company reports quarterly, with next earnings expected on November 13, 2025."},{"question":"What's the biggest risk with investing in CRDL?","answer":"Clinical trial failure is the primary risk\u2014negative results could significantly impact the stock price."},{"question":"Should I invest for short-term or long-term gains?","answer":"CRDL is better suited for long-term investors (3-5 years) who can withstand volatility while awaiting clinical milestones and potential FDA approvals."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is Cardiol Therapeutics profitable?","answer":"No, CRDL is a clinical-stage company currently reporting losses as it invests heavily in research and development. The Q2 2025 net loss was $8.35 million."},{"question":"What makes CRDL different from other biotech stocks?","answer":"Cardiol focuses exclusively on cardiovascular inflammation and fibrosis\u2014specialized areas with high unmet medical needs and limited competition."},{"question":"How often does CRDL release earnings reports?","answer":"The company reports quarterly, with next earnings expected on November 13, 2025."},{"question":"What's the biggest risk with investing in CRDL?","answer":"Clinical trial failure is the primary risk\u2014negative results could significantly impact the stock price."},{"question":"Should I invest for short-term or long-term gains?","answer":"CRDL is better suited for long-term investors (3-5 years) who can withstand volatility while awaiting clinical milestones and potential FDA approvals."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Cardiol Therapeutics Inc. (CRDL) shares - Investment in Cardiol Therapeutics Inc. (CRDL) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Cardiol Therapeutics Inc. (CRDL) shares - Investment in Cardiol Therapeutics Inc. (CRDL) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T13:52:13+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Cardiol Therapeutics Inc. (CRDL) shares &#8211; Investment in Cardiol Therapeutics Inc. (CRDL) stock\",\"datePublished\":\"2025-08-25T13:52:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\",\"name\":\"How to buy Cardiol Therapeutics Inc. (CRDL) shares - Investment in Cardiol Therapeutics Inc. (CRDL) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"datePublished\":\"2025-08-25T13:52:13+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Cardiol Therapeutics Inc. (CRDL) shares &#8211; Investment in Cardiol Therapeutics Inc. (CRDL) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Cardiol Therapeutics Inc. (CRDL) shares - Investment in Cardiol Therapeutics Inc. (CRDL) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Cardiol Therapeutics Inc. (CRDL) shares - Investment in Cardiol Therapeutics Inc. (CRDL) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T13:52:13+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Cardiol Therapeutics Inc. (CRDL) shares &#8211; Investment in Cardiol Therapeutics Inc. (CRDL) stock","datePublished":"2025-08-25T13:52:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/","name":"How to buy Cardiol Therapeutics Inc. (CRDL) shares - Investment in Cardiol Therapeutics Inc. (CRDL) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","datePublished":"2025-08-25T13:52:13+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Cardiol Therapeutics Inc. (CRDL) shares &#8211; Investment in Cardiol Therapeutics Inc. (CRDL) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":348125,"slug":"how-to-buy-cardiol-therapeutics","post_title":"Comment acheter des actions de Cardiol Therapeutics Inc. (CRDL) - Investissement dans les actions de Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"it_IT":{"locale":"it_IT","id":348126,"slug":"how-to-buy-cardiol-therapeutics","post_title":"Come acquistare azioni Cardiol Therapeutics Inc. (CRDL) - Investire in azioni Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"pl_PL":{"locale":"pl_PL","id":348127,"slug":"how-to-buy-cardiol-therapeutics","post_title":"Jak kupi\u0107 akcje Cardiol Therapeutics Inc. (CRDL) - Inwestycja w akcje Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"es_ES":{"locale":"es_ES","id":348130,"slug":"how-to-buy-cardiol-therapeutics","post_title":"C\u00f3mo comprar acciones de Cardiol Therapeutics Inc. (CRDL) - Inversi\u00f3n en acciones de Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"th_TH":{"locale":"th_TH","id":348128,"slug":"how-to-buy-cardiol-therapeutics","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Cardiol Therapeutics Inc. (CRDL) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"tr_TR":{"locale":"tr_TR","id":348131,"slug":"how-to-buy-cardiol-therapeutics","post_title":"Cardiol Therapeutics Inc. (CRDL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cardiol Therapeutics Inc. (CRDL) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"vt_VT":{"locale":"vt_VT","id":348132,"slug":"how-to-buy-cardiol-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Cardiol Therapeutics Inc. (CRDL) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":348129,"slug":"how-to-buy-cardiol-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Cardiol Therapeutics Inc. (CRDL) - Investimento em a\u00e7\u00f5es da Cardiol Therapeutics Inc. (CRDL)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-cardiol-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=348040"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348040\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334126"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=348040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=348040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=348040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}